ライフサイエンスコーパス: serum marker

1 by liver biopsy, transient elastography, or serum markers).

2 s instituted prospectively on the basis of a serum marker.

3 with further improvement upon integration of serum markers.

4 ondiagnostic electrocardiograms and negative serum markers.

5 ssion was documented by biopsy or increasing serum markers.

6 lates with the body mass index and metabolic serum markers.

7 r cannot explain racial disparities in these serum markers.

8 avior were comparable with that of other IBD serum markers.

9 CT perfusion parameters with tumor grade and serum markers.

10 relation between CT perfusion parameters and serum markers.

11 Parameters were correlated with HCC serum markers.

12 ere documented in blood eosinophil counts or serum markers after eHF intake.

13 However, when the values of known serum markers alpha fetoprotein, des-gamma carboxyprothr

14 Serum markers also appear to provide useful prognostic i

15 naire and metabolic risks were determined by serum markers and anthropometric measures at pre- and po

16 sure mitochondrial absorbance, infarct size, serum markers and apoptotic index.

17 c inflammation was assessed by histology and serum markers and fibrosis by collagen proportionate are

18 At the current writing, serum markers and imaging methods are available and incr

19 A combination of serum markers and imaging tools appears useful in reduci

20 ltahepa) or control mice, based on levels of serum markers and microscopic and histologic analysis of

21 The relationship between serum markers and quantitative hepatic collagen content

22 e of the newer noninvasive methods including serum markers and radiologic tests.

23 ve adverse vascular effects not reflected in serum markers and that nonlipid macronutrients can modul

24 A sequential approach or the combination of serum markers and transient elastography is able to sign

25 ue to frequent late-stage diagnosis, lack of serum markers, and limited information regarding biliary

26 s of recovery, such as genetic associations, serum markers, and the impact of medical therapy or vent

27 Available diagnostic serum markers are not sensitive or specific enough, and

28 Ghr(-/-);Mdr2(-/-) mice showed elevated serum markers associated with liver damage and cholestas

29 Serum markers associated with the acute proinflammatory

30 Guidelines recommend that testing for serum markers be repeated every 12-24 weeks during antiv

31 More-reliable serum markers, better tumour localisation and identifica

32 We compared YKL-40 with two ovarian cancer serum markers, CA125 and CA15-3, for the detection of ea

33 erated diagnostic protocols with new cardiac serum markers can detect myocardial ischemia or infarcti

34 ine decarboxylase (HDC) gene expression; and serum markers (CCL2, CCL5, CCL11, IL-3, and thymic strom

35 od to assess the prognostic value of CTC and serum marker changes during treatment.

36 Serum marker determinations at baseline and 60-min after

37 Frequent serum marker determinations to estimate marker decline d

38 hy scans, bronchoalveolar lavage and various serum markers (e.g., surfactant protein D and KL-6) each

39 es emphasized are computer-generated models, serum markers, echocardiography, and nuclear imaging in

40 Among nonlipid serum markers examined, only C-reactive protein levels a

41 gression including metabolomics, circulating serum markers, exercise physiology, and both structural

42 ific antigen (PSA) has been widely used as a serum marker for cancer of the prostate.

43 e cancer (PCa) and is the most commonly used serum marker for cancer.

44 PCT is a reliable serum marker for determining the presence or absence of

45 Chromogranin A appears to be the most useful serum marker for diagnosis, staging, and monitoring.

46 We have identified a potential serum marker for glioblastoma multiforme (GBM) using mic

47 The conventional serum marker for HB, alpha-fetoprotein (AFP), has its li

48 concluded that GPC3 is inferior to AFP as a serum marker for HB.

49 increasing grade of ACR and may be a useful serum marker for intestinal rejection.

50 There is no known serum marker for intestinal rejection.

51 d and neck cancer and represents a promising serum marker for monitoring affected patients.

52 results merit further investigation of this serum marker for potential diagnostic and prognostic pur

53 tate-specific antigen (PSA) is a widely used serum marker for prostate cancer (PCa) but has limited s

54 tate specific antigen (PSA) is a widely used serum marker for prostate cancer (PCa), but has limited

55 tate-specific antigen (PSA) is a widely used serum marker for prostate cancer (PCa), but in the criti

56 , previously known as CA125, is a well-known serum marker for the diagnosis of ovarian cancer and has

57 the potential of this protein to serve as a serum marker for the early stage diagnosis of PC.

58 ApoM levels may be a useful serum marker for the identification of MODY3 patients.

59 Methods for the determination of serum markers for bone and cartilage destruction, as wel

60 veloped massive cardiac damage as defined by serum markers for cardiomyocyte cell death, electrocardi

61 y in hematopoietic tissues and are potential serum markers for certain hematopoietic malignancies.

62 This study sought to determine if serum markers for collagen I and III synthesis, the carb

63 CCSA-3 and CCSA-4 show promise as potential serum markers for detection of colorectal cancer and adv

64 the proposed intervention and identify early serum markers for each of those subgroups.The mathematic

65 ents (30%) and 3 of 59 controls (5%) without serum markers for HBV infection.

66 tly, there remains a great need for reliable serum markers for IBD.

67 nd inflammatory responses and serve as early serum markers for monitoring acute allograft rejection.

68 ntibodies against citrullinated proteins and serum markers for osteoclast-mediated bone resorption in

69 Her white blood cell count and serum markers for ovarian cancer were normal (alpha-feto

70 Detection of serum markers for pancreatic cancer has been elusive.

71 large-scale proteomics to identify potential serum markers for pancreatic cancer.

72 ometry successfully identified 154 potential serum markers for pancreatic cancer.

73 ts suggest that both CYT-MAA and HMW-MAA are serum markers for residual melanoma in patients with res

74 Serum markers for the diagnosis of early HCC (<2 cm in d

75 and a literature search to select candidate serum markers for the diagnosis of lung cancer.

76 The measurement of infarct size by serum markers has multiple theoretical and practical lim

77 in whom postoperative elevations of cardiac serum markers have been correlated to medium- and long-t

78 ge of targeted therapies and as a diagnostic serum marker in cancer, is confounded by its variable tu

79 o support recommendations for using nonlipid serum markers in decisions regarding statin therapy for

80 imaging data were supported by modulation of serum markers in vitro and ex vivo histopathology.

81 Serum markers include chromogranin A for neuroendocrine

82 rol and rmTSG-6-treated animals when various serum markers (including pro- and anti-inflammatory cyto

83 Novel serum markers, including C-reactive protein and homocyst

84 Analysis of serum markers indicated that 95% (84/88) had evidence of

85 neoplasia could make this protein a possible serum marker indicating the presence of high-risk premal

86 ly history of liver cancer and hepatitis B/C serum markers is associated with an over 70-fold elevate

87 Use of Feno values, bEOS counts, and serum marker levels (eg, CCL26 and CCL17) in combination

88 Furthermore, proinflammatory serum markers may be used as inclusion criteria or endpo

89 Novel serum markers need to be explored.

90 ents were analyzed for cardiac troponin I, a serum marker not detected in the blood of healthy person

91 el candidate for development as a diagnostic serum marker of early stage colon cancer.

92 FibroTest is an indirect serum marker of hepatic fibrosis.

93 nce of procalcitonin (ProCT), an established serum marker of infection, in saliva.

94 A reliable noninvasive serum marker of IRA patency is desired to permit early i

95 e HIP1 autoantibody test may be an important serum marker of prostate cancer.

96 sTac has been used as a serum marker of T cell activation in immune disorders an

97 eptide of calcitonin, has been shown to be a serum marker of the severity and mortality of several sy

98 gned to assess safety, pharmacokinetics, and serum markers of angiogenesis in patients with solid tum

99 Serum markers of angiogenic activity did not provide ins

100 e consistent hyposecretors of acid, most had serum markers of atrophic gastritis.

101 n total serum bile acid (BA) concentrations, serum markers of BA synthesis and steady-state pharmacok

102 ne levels were normal (35 +/- 21 pg/ml), the serum markers of bone formation (osteocalcin and bone-sp

103 on in bone, loss of osteoblasts, and reduced serum markers of bone formation, including osteocalcin a

104 hose discontinuing alendronate had increased serum markers of bone turnover compared with continuing

105 Serum markers of bone turnover were also determined.

106 lasts, Shn3-deficient animals show decreased serum markers of bone turnover.

107 respective gene expression in liver and the serum markers of circadian function.

108 The goal of this study was to identify novel serum markers of colon cancers and precancerous colon ad

109 creatinine level, urinary protein level, and serum markers of disease activity.

110 -defined patient population for the study of serum markers of familial OA with respect to pathogenesi

111 re, Braak score, and 11C-PiB retention, with serum markers of glucose homeostasis using grouped and c

112 oad, and a decrease in both GCF IL-1beta and serum markers of IL-6 response.

113 cell function, lymphocyte surface phenotype, serum markers of immunologic activation, and viral burde

114 rt Form 36 health survey questionnaire), and serum markers of inflammation (erythrocyte sedimentation

115 Serum markers of inflammation (high-sensitivity C-reacti

116 Serum markers of inflammation and oxidation were also me

117 Hormone therapy has divergent effects on serum markers of inflammation in women with CAD.

118 Anemia and serum markers of inflammation were present in all cases.

119 roups had similar fecal microbiota profiles, serum markers of inflammation, and levels of neurotrophi

120 fecal microbiota, urine metabolome profiles, serum markers of inflammation, neurotransmitters, and ne

121 erythematous left index finger and elevated serum markers of inflammation.

122 tion analysis to address the contribution of serum markers of liver damage, high aspartate (AST, >49.

123 Knowledge of serum markers of liver decompensation would facilitate c

124 d is sufficient for preventing elevations in serum markers of liver dysfunction in this population un

125 Serum markers of liver function were used to evaluate LR

126 high-resolution CT (HRCT) abnormalities and serum markers of lung fibrosis.

127 rmined that DPD in mice and humans increases serum markers of metabolic health.

128 e displayed increased inflammation, enhanced serum markers of myocardial damage, and an increased inf

129 st groups with a similar trends observed for serum markers of myocardial injury and apoptotic index.

130 aim of this study was to assess the role of serum markers of myocardial necrosis after cardiac surge

131 growth and should be considered as potential serum markers of neoplastic prostate diseases.

132 osition, apoptosis, histologic features, and serum markers of oxidative stress (OS) and cell death in

133 with stable plaques, and may correlate with serum markers of plaque instability and inflammation.

134 to examine associations between SBI and two serum markers of renal function: Serum creatinine (SCr)

135 Serum markers of renal injury were significantly decreas

136 Currently, quantification of pretransplant serum markers of the HBV antigen load does not predict t

137 chemokine 10, in parallel with depression of serum markers of the myeloid cell activation, such as CC

138 ve developed a process for identification of serum markers of this disease based upon standardized fr

139 Established serum markers of tumor spread were measured serially and

140 weeks of gestation, did not reduce systemic (serum) markers of inflammation.

141 umor cells along with reduction in malignant serum markers (osteopontin, Cxcl12) were noted.

142 To date, a number of methods including serum marker panels and ultrasound-based transient elast

143 Serum marker panels, initially developed for determining

144 iew is broad and includes topics such as the serum marker procalcitonin, gene expression profiling, m

145 A standard amphotropic vector expressing a serum marker protein, human alpha 1-antitrypsin, was inf

146 Serum markers related to bone turnover, calcium, phospho

147 Serum markers such as myoglobin and creatine kinase, MB

148 Previous genetic studies of blood group and serum markers suggested that Jewish groups had Middle Ea

149 regarding the measurement of infarct size by serum markers, technetium-99m sestamibi single-photon em

150 mes, it is desirable to identify a sensitive serum marker that is closely related to the degree of my

151 proteomic analysis in an attempt to discover serum markers that can assist in the early detection of

152 Finally, we sought to identify serum markers that differentiate SIRS with and without i

153 Longitudinal physiologic and serum markers, time of death.

154 Although PSA is the most widely used serum marker to detect and follow patients with prostati

155 We assessed the added value of CTCs or serum markers to prognostic clinicopathological models i

156 Assessment of liver fibrosis with multiple serum markers used in combination is sensitive, specific

157 A panel of 10 diabetes and obesity serum markers was determined using MAGPIX.

158 d the slope of increase over 60 min for each serum marker were significantly higher in patients with

159 of detection of Down's syndrome for the five serum markers were as follows: 17 percent for alpha-feto

160 CCL2 levels (but not those of other serum markers) were significantly higher during anaphyla

161 ated significantly and better than any other serum marker with apoptosis and liver damage, such as ba

162 ent of cardiac troponin I (cTnI), which is a serum marker with high sensitivity and specificity for c

163 The stronger correlation of the serum markers with Ishak scores suggests that serum fibr

164 in saturation (SaO(2)) during sleep] and all serum markers with pain thresholds and tolerances at bas

165 ular epithelial cells, and lower cholestasis serum markers within 2 weeks after DDC treatment.

166 assess whether the immediate availability of serum markers would increase the appropriate use of thro